Penn Researchers Find Chemoembolization Effective For Liver Tumors

March 24, 1999

Chemotherapy Delivered Directly to Liver Tumors Doubles Life Expectancy

(Philadelphia, PA) -- More than 150,000 new cases of colon cancer are diagnosed each year, and, for half of these patients, the disease spreads to the liver. A Phase-II study performed by a team of researchers at the University of Pennsylvania Medical Center has found that a minimally invasive technique known as chemoembolization may double the survival time of adult patients with colon cancer that has spread to the liver. Michael C. Soulen, MD, associate professor of radiology at Penn and senior author of the study, will present these findings at the 24th Annual Scientific Meeting of the Society of Cardiovascular & Interventional Radiology (SCVIR) on Wednesday, March 24, in Orlando, Florida.

Systemic chemotherapy delivers cancer-killing medication into the bloodstream where it travels throughout the body and eventually reaches the tumor. In contrast, chemoembolization works by delivering chemotherapy directly to cancerous cells with the use of a non-surgical, interventional catheterization technique. This technique also involves the infusion of tiny particles that cut off the blood supply to the tumor, thus inhibiting cancer-cell growth. Colon cancer that has metastasized, or spread, can be managed with chemoembolization when systemic chemotherapy has failed. "Chemoembolization hones in on the cancerous cells that have spread to the liver and avoids exposing the rest of the body to chemotherapy's toxic effects," explains Dr. Soulen. "This technique is not a cure, but it can extend patients' lives and preserve their quality of life."

In this study, 51 patients whose colon cancer had metastasized to the liver were treated with chemoembolization. Eighty-six percent (86%), or 44 of the patients, survived one year after treatment. The patients in this study survived an average of two years. Typically, less than half of liver cancer patients survive one year after undergoing systemic chemotherapy.

Chemoembolization is performed while the patient is under conscious sedation, and is administered by an interventional radiologist. The procedure involves making a small needle puncture in the patient's groin and inserting a catheter, or tiny tube, into the liver's hepatic artery. Using a moving X-Ray, the arteries to the liver are identified and three chemotherapy drugs are delivered directly to the hepatic artery leading to the tumor -- thus sparing healthier liver tissue. The hepatic artery is then blocked off, or embolized, with a mixture of oil and tiny particles. This technique deprives the tumor of fortifying oxygen and nutrients, while saturating the tumor with high doses of medication. Chemoembolization is effective without damaging the liver because the hepatic artery is central to the tumor's survival, however it provides only twenty-five percent (25%) of the liver's blood supply. The liver is unique in that it has two blood supplies -- a hepatic artery as well as a large portal vein that furnishes ample blood flow on its own.

The chemoembolization procedure is approximately three hours in length, and involves an overnight hospital stay. It is performed repeatedly on a monthly basis, with an average treatment regimen of approximately three sessions.

"With chemoembolization we can offer a less taxing and effective treatment for liver cancer," said Dr. Soulen. "Although not curative, it can extend and preserve a more normal life for the patient by minimizing the cancer and its effects."
-end-
Editor's Notes:
Dr. Soulen can be reached directly at 215-662-7111. From March 17 - 25, please contact Sue Montgomery to reach him at the SCVIR annual meeting in Orlando.



University of Pennsylvania School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.